Strategic pharmaceutical alliances symbolized by interconnected molecules.

Pharma Giants Pfizer and Celgene Strategically Expand Portfolios for Future Growth

Reese Marlowe monogram
Reese Marlowe in Health & Wellness October 2026 • 3 min read.

"Recent moves by Pfizer and Celgene highlight a renewed focus on strategic acquisitions, innovative drug development, and sustainable practices."


The pharmaceutical industry is in constant flux, driven by the need for innovation, growth, and adaptation to evolving market dynamics. Recent strategic moves by industry giants like Pfizer and Celgene illustrate these trends, with a focus on acquiring promising assets, developing innovative therapies, and embracing sustainable practices.

Pfizer, after abandoning its merger with Allergan due to unfavorable tax rule changes, is now focusing on smaller, strategic acquisitions to bolster its new product portfolio. Meanwhile, Celgene is expanding its reach through collaborations aimed at pioneering new approaches in drug development, particularly in immuno-oncology.

These developments reflect a broader industry trend towards precision medicine, sustainable manufacturing, and strategic partnerships to drive innovation and address unmet medical needs. By examining these specific cases, we can gain insights into the strategies that are shaping the future of pharmaceuticals.

AI Search Multiple angles on this topic

Platform Access and Automation

The available materials focus on YouTube TV and OBS rather than pharmaceutical portfolio expansion. YouTube TV states that viewers outside their home area can watch local programming where they are, but cannot record or watch networks local to their home area. OBS Studio is available for Windows, Mac, and Linux, while its Advanced Scene Switcher plugin uses condition-and-action macros to automate tasks.

Evidence Limitations

No subsection-specific sources were provided for established methods or their limitations. Any assessment of standard approaches would therefore be general rather than evidence-led. The available material does not support conclusions about pharmaceutical research or portfolio strategy.

Historical Context

No sources were supplied for the historical development of the topic. A responsible historical account would require documented milestones, dates, and foundational discoveries. Those details cannot be established from the available subsection material.

Pfizer's Strategic Acquisition of Anacor Pharmaceuticals

Strategic pharmaceutical alliances symbolized by interconnected molecules.

In a significant move to strengthen its dermatology pipeline, Pfizer has acquired Anacor Pharmaceuticals for approximately $5.2 billion. Anacor, a biotech firm specializing in boron-containing small-molecule therapeutics, brings to Pfizer a promising treatment for eczema, crisaborole, which is currently under FDA review.

Crisaborole, a topical treatment for eczema, has the potential to generate peak annual sales of $2 billion or more, according to Pfizer. This optimism is based on the fact that a novel eczema treatment has not been approved in over 15 years, highlighting the significant unmet need in this therapeutic area.

  • Novel Mechanism: Crisaborole leverages boron's unique ability to form coordinate covalent bonds, enhancing drug-target interaction.
  • Strategic Fit: The acquisition aligns with Pfizer's strategy to focus on innovative, patent-protected products after its failed attempt to merge with Allergan.
  • Market Potential: With a potential $2 billion in peak annual sales, crisaborole could become a key growth driver for Pfizer's dermatology franchise.
AI Search Multiple angles on this topic

Research Evidence

No sources were provided for recent research or review literature. The subsection can therefore support only a cautious statement that current evidence is not documented in the supplied material. Specific findings about Pfizer, Celgene, or portfolio expansion would require additional sources.

Access and Usability Problems

The supplied Airbnb Community reports describe practical difficulties for hosts trying to access their accounts and listings. One user said they could log in online but could find only the Community page rather than the hosting page, while another described difficulty editing a profile, photos, description, and pricing despite knowing the username and password. A separate question also asks how to access the dashboard without manually entering its URL, suggesting that navigation and account access were recurring usability concerns.

Comparison Constraints

No subsection-specific sources were supplied for a comparative analysis. Comparisons among pharmaceutical companies, products, or portfolio strategies would therefore be speculative. The available evidence does not establish comparable measures, time periods, or outcomes.

Founded in 2002, Anacor has focused on leveraging boron's unique chemical properties to create novel therapeutics. For Pfizer, this acquisition represents a strategic shift towards smaller, more targeted deals aimed at quickly enhancing its product offerings and market position. This approach allows Pfizer to remain agile and responsive to market opportunities without the complexities and risks associated with large-scale mergers.

Looking Ahead: Strategic Imperatives for Pharma

The moves by Pfizer and Celgene underscore critical strategic imperatives for pharmaceutical companies in today's dynamic environment. These include a focus on targeted acquisitions, innovative drug development, and sustainable practices. By embracing these strategies, companies can position themselves for long-term success and contribute to the advancement of healthcare.

AI Search Multiple angles on this topic

Evidence-Based Synthesis

No sources were provided for synthesis or expert commentary. Any interpretation should remain provisional because the supplied material does not address Pfizer, Celgene, or pharmaceutical portfolio decisions. Stronger conclusions would require directly relevant corporate, clinical, or market evidence.

Future Evidence Needs

No subsection-specific sources support forecasts or discussion of emerging frontiers. Future-oriented claims about pharmaceutical growth would consequently be speculative. A grounded outlook would require documented pipeline, regulatory, commercial, or scientific information.

Tracking Across Regions

FedEx provides shipment-tracking services in the United States, the United Kingdom, and India. Across these pages, users can enter a tracking number, track by reference, obtain proof of delivery, or use a TCN. The repeated functionality shows a common tracking framework presented across regional FedEx sites, although the supplied material does not establish broader systemic effects.

Human Impact

No sources were supplied for the human or real-world effects of the article's subject. It is therefore appropriate to avoid attributing patient, employee, or community outcomes without supporting evidence. A substantive treatment would require sources describing how the relevant decisions affect people in practice.

Pfizer's clinical success rate against industry benchmarks

  • 21% versus about 11% clinical success rateBy the end of 2020, Pfizer’s end-to-end clinical success rate was 21%, compared with an industry benchmark of about 11%.[1]
  • 85% versus 72% late-stage success ratePfizer’s late-stage success rate was 85%, while the industry rate was 72%.[1]

What Pfizer's trial figures suggest

The figures indicate that Pfizer’s stronger overall clinical success rate coincided with higher success at both the mid-stage and late-stage points reported. They describe development performance, but do not establish that acquisitions caused the results or that any particular product will succeed.[1]

The reported Phase II comparison also shows that Pfizer’s advantage was not confined to the final stages of testing; the figures do not identify what produced that difference.[1]

Acquisitions, development outcomes, and competition

The sector shifted from 60 firms in 1995 to 10 global pharmaceutical companies by 2015 through mergers and acquisitions, placing portfolio expansion within a broader consolidation pattern.[2]

Research on mergers and acquisitions reports a tension: development projects are more likely to be discontinued, while the candidates that continue may progress through clinical phases faster.[2]

When merging firms’ research overlaps, the reported downside from discontinuations is reinforced, while the acceleration in clinical progress is no longer significant.[2]

A separate competition case concerned a proposed acquisition involving Celgene’s popular oral psoriasis treatment. The regulator alleged that the deal could lessen competition; the proposed consent agreement was intended to preserve competition in that market, not to establish a clinical effect.[3]

What the acquisition evidence leaves unresolved

  • If research activities overlap, which projects are discontinued and which advance faster? The reported pattern describes opposing effects but does not specify the outcome for a particular portfolio.[2]
  • How would a new competitor overcome the time, investment, regulatory, clinical-history, and sales-infrastructure barriers described for entry into the psoriasis market?[3]
  • Would preserving competition through the proposed agreement change market conditions over time? The described allegation and remedy do not report later market outcomes.[3]

Terms used in acquisition and development

Mergers and acquisitions
M&As[2]
Phosphodiesterase 4 inhibitor
The class identified for apremilast, marketed as Otezla.[3]

Sources

  1. Achieving end-to-end success in the clinic: Pfizer’s learnings on R&D productivity (pmc.ncbi.nlm.nih.gov)
  2. Study on the impact of mergers and acquisitions on innovation in the pharmaceutical sector - Publications Office of the EU(Opens New Window) (op.europa.eu)
  3. Analysis of Agreement Containing Consent Orders To Aid Public Comment (www.ftc.gov)

About this Article -

Written with AI assistance from published research, and reviewed by the Mystum team. See our About page for more information.

Everything You Need To Know

1

What was the primary motivation behind Pfizer's acquisition of Anacor Pharmaceuticals?

Pfizer's primary motivation for acquiring Anacor Pharmaceuticals was to bolster its dermatology pipeline with crisaborole, a promising treatment for eczema. This acquisition reflects Pfizer's strategic shift towards smaller, more targeted deals following the abandonment of its merger with Allergan. Crisaborole, with its novel mechanism and potential for significant sales, offered Pfizer a rapid way to enhance its product offerings and market position, aligning with its focus on innovative, patent-protected products.

2

How does crisaborole work, and why is it considered a significant advancement in eczema treatment?

Crisaborole is a topical treatment for eczema that leverages boron's unique ability to form coordinate covalent bonds, enhancing drug-target interaction. This novel mechanism sets it apart from existing treatments. Crisaborole's significance lies in the fact that no new eczema treatment has been approved in over 15 years, indicating a significant unmet medical need. With the potential to generate peak annual sales of $2 billion or more, crisaborole could become a key growth driver for Pfizer's dermatology franchise, offering a much-needed solution for patients.

3

What strategic imperatives are highlighted by the actions of Pfizer and Celgene in the pharmaceutical industry?

The actions of Pfizer and Celgene highlight critical strategic imperatives for pharmaceutical companies. These include a focus on targeted acquisitions, innovative drug development, and sustainable practices. Pfizer's acquisition of Anacor exemplifies targeted acquisitions, while Celgene's collaborations for drug development demonstrate a commitment to innovation. Both companies' moves reflect a broader industry trend towards precision medicine, sustainable manufacturing, and strategic partnerships to drive innovation and address unmet medical needs, positioning them for long-term success.

4

Why did Pfizer opt for smaller, strategic acquisitions like Anacor instead of pursuing large-scale mergers like the one with Allergan?

Pfizer shifted its strategy towards smaller, strategic acquisitions after abandoning its merger with Allergan due to unfavorable tax rule changes. This new approach allows Pfizer to remain agile and responsive to market opportunities without the complexities and risks associated with large-scale mergers. The acquisition of Anacor, for instance, allowed Pfizer to quickly enhance its product offerings with a promising treatment like crisaborole, reflecting a strategic focus on innovation and patent-protected products to drive growth.

5

How are Celgene's collaborations contributing to innovation in the pharmaceutical landscape, and what area of drug development is it particularly focused on?

Celgene is expanding its reach through collaborations, aiming at pioneering new approaches in drug development, particularly in immuno-oncology. Although the specific details of Celgene's collaborations are not fully detailed, the general trend highlights the importance of strategic partnerships in driving innovation. These collaborations enable Celgene to explore new avenues and technologies, contributing to advancements in precision medicine and addressing unmet medical needs. Such partnerships allow for shared expertise and resources, accelerating the development of innovative therapies in areas like immuno-oncology.

Newsletter Subscribe

Subscribe to get the latest articles and insights directly in your inbox.